Pharmaceuticals News and Research

RSS

NextWave Pharmaceuticals, Tris Pharma sign agreement to enhance CNS product portfolio

NextWave Pharmaceuticals and Tris Pharma, both privately held companies, announced a new collaboration agreement to enhance NextWave's CNS product portfolio utilizing Tris Pharma's unique drug delivery technology for liquid and solid formulations. Tris has reacquired the rights to non CNS products including all the OTC products previously licensed to NextWave Pharmaceuticals.

12 Aug 2010

FDA advisory committee votes in favor of Ezogabine

The U.S. Food and Drug Administration advisory committee voted unanimously that clinical studies had provided substantial evidence of the effectiveness of Ezogabine (known as Retigabine outside of the U.S.) as adjunctive treatment for adults with partial-onset seizures.

12 Aug 2010

Entry deadline for second annual CLIO Healthcare Awards extended to August 27, 2010

The entry deadline has been extended for the second annual CLIO Healthcare Awards. All work appearing between January 1, 2009 and June 30, 2010 must be submitted to the CLIO Healthcare Awards no later than August 27, 2010. In an effort to provide an innovative and eco-friendly entry process, once again the CLIO Healthcare Awards will receive submissions online only at www.CLIOHealthcare.com. Professionals now have additional time to refine their entries, including international work, made eligible for the first time.

12 Aug 2010

Evotec revenues for first-half of 2010 increase 33% to € 25.0 m

Evotec AG today reported financial results and corporate updates for the first half of 2010.

12 Aug 2010

AVEO achieves enrollment target for tivozanib global Phase 3 clinical trial in advanced renal cell carcinoma

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has achieved its enrollment target for TIVO-1, its global Phase 3 clinical trial for its oral, triple VEGF receptor inhibitor, tivozanib, in patients with advanced renal cell carcinoma. In February of this year, AVEO initiated enrollment in TIVO-1, and has successfully reached the target enrollment of 500 patients.

12 Aug 2010

Simcere second-quarter total revenue increases 28.3% to RMB544.6 million

12 Aug 2010

Simcere subsidiary receives Chinese SFDA approval to manufacture and market Palonosetron

Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that its subsidiary company Simcere Dongyuan Pharmaceutical Co., Ltd. has recently received SFDA new drug certification and registration approval to manufacture and market Palonosetron material and injections in China.

12 Aug 2010

Somaxon second-quarter net loss reduces to $5.7 million

Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced financial results for the second quarter ended June 30, 2010.

12 Aug 2010

Seattle Genetics, Genentech expand antibody-drug conjugate collaboration

Seattle Genetics, Inc. announced today that it has expanded its antibody-drug conjugate (ADC) collaboration agreement with Genentech, Inc., a member of the Roche Group. Under the expanded agreement, Genentech will pay an upfront fee of $12 million for rights to utilize Seattle Genetics' ADC technology with additional antigens to be named by Genentech.

12 Aug 2010

FDA advisory committee votes in favor of investigational anti-epileptic drug ezogabine

GlaxoSmithKline and Valeant Pharmaceuticals International announced today that a U.S. Food and Drug Administration advisory committee voted unanimously that clinical studies had provided substantial evidence of the effectiveness of ezogabine as adjunctive treatment for adults with partial-onset seizures.

12 Aug 2010

Intellect Neurosciences receives patent for insulin sensitizer drugs

Intellect Neurosciences, Inc., a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced today that its Chairman & CEO, Dr. Daniel Chain, was granted a patent by the European Patent and Trademark Office related to the use of insulin sensitizers for the prevention and treatment of memory loss and dementia. Insulin sensitizer drugs include Rosiglitazone and Pioglitazone, which have been approved for the treatment of type II diabetes mellitus.

12 Aug 2010

American Medical Alert second-quarter net income increases 30% to $791,418

American Medical Alert Corp.a provider of healthcare communication services and advanced telehealth monitoring technologies, today announced operating results for the quarter and six months ended June 30, 2010.

12 Aug 2010

MedThink Connect Web online communications tool enables face-to-face interaction with experts

MedThink Communications, a full-service healthcare communications company, today announced the launch of MedThink Connect™, a new, customizable Web application that provides healthcare companies a vehicle to efficiently seek guidance, maintain interaction, and build a community atmosphere with external experts. MedThink Connect allows users to advance their relationships with external experts, including advisors, investigators, spokespeople, patients, and speakers.

12 Aug 2010

Syndax raises $6 million to support ENCORE 301 study in breast cancer

Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, today announced that it has issued $6M in convertible notes and warrants to its Series A investors bringing the total investment to date to $55M. All current investors, including Domain Associates, MPM Capital, Avalon Ventures, Forward Ventures, Pappas Ventures and MC Life Sciences participated in the securities offering.

12 Aug 2010

NeoStem, Schepens Eye Research Institute collaborate to develop therapies for AMD and Glaucoma

NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, announced today that it has entered into a sponsored research agreement (SRA) with the Schepens Eye Research Institute, a charitable corporation of Massachusetts and an affiliate of Harvard Medical School.

12 Aug 2010

AHF led sustained advocacy campaign leads to BMS's offer of discounts in AIDS drug pricing

Following ongoing advocacy campaigns spearheaded by AIDS Healthcare Foundation (AHF) that targeted several of the largest AIDS drug companies over their pricing and rebate policies for the nation's AIDS Drug Assistance Programs (ADAPs), the federally funded, state run programs that supply lifesaving AIDS drugs to low-income Americans in need, that the last remaining major AIDS drug company, Bristol-Myers Squibb (BMS) today announced an agreement that will provide additional cost savings to cash-strapped ADAPs nationwide.

12 Aug 2010

Furiex second-quarter 2010 revenues increase to $8.1M from $0.2M in second-quarter 2009

Furiex Pharmaceuticals, Inc. today reported its financial and operating results for the quarter ended June 30, 2010. Furiex was spun off from PPD, Inc. effective June 14, 2010. The financial information included in the financial and operating results does not reflect the consolidated results of operations or cash flows of the company had it been a separate, stand-alone entity during the periods presented as the information through June 14, 2010, was derived from PPD's discovery sciences segment.

12 Aug 2010

Smoking rates continue to fall in Japan

Japan has set a world record with the 15th consecutive year of low smoking rates according to a nationwide survey released Wednesday by Japan Tobacco Inc.

11 Aug 2010

Mental health bill for 2008 was $5.3 billion: Report

According to the Australian Institute of Health and Welfare (AIHW), the country is spending more and more to deal with its mental ailment burden. This emerged from a report from the AIHW saying that finances spent on mental health services between 2007 to 2008 were $5.3 billion. Of this around 60 per cent came from state and territory governments, 36 per cent from the Commonwealth, and the rest from private health funds.

11 Aug 2010

HemaQuest commences HQK-1004 global Phase 2 clinical trial in EBV-related malignancies

HemaQuest Pharmaceuticals announced today that it has initiated the Company's Phase 2 clinical trial evaluating its proprietary HQK-1004 therapy for the treatment of lymphomas and related cancers associated with Epstein-Barr virus (EBV) infection. These EBV-related cancers have poor prognoses and short patient survival. Currently available cancer therapies are typically much less effective in patients with EBV-related lymphoid malignancies than in patients who have similar cancers not infected with the virus.

11 Aug 2010

Pharmaceuticals News and Research

NextWave Pharmaceuticals, Tris Pharma sign agreement to enhance CNS product portfolio

FDA advisory committee votes in favor of Ezogabine

Entry deadline for second annual CLIO Healthcare Awards extended to August 27, 2010

Evotec revenues for first-half of 2010 increase 33% to € 25.0 m

AVEO achieves enrollment target for tivozanib global Phase 3 clinical trial in advanced renal cell carcinoma

Simcere second-quarter total revenue increases 28.3% to RMB544.6 million

Simcere subsidiary receives Chinese SFDA approval to manufacture and market Palonosetron

Somaxon second-quarter net loss reduces to $5.7 million

Seattle Genetics, Genentech expand antibody-drug conjugate collaboration

FDA advisory committee votes in favor of investigational anti-epileptic drug ezogabine

Intellect Neurosciences receives patent for insulin sensitizer drugs

American Medical Alert second-quarter net income increases 30% to $791,418

MedThink Connect Web online communications tool enables face-to-face interaction with experts

Syndax raises $6 million to support ENCORE 301 study in breast cancer

NeoStem, Schepens Eye Research Institute collaborate to develop therapies for AMD and Glaucoma

AHF led sustained advocacy campaign leads to BMS's offer of discounts in AIDS drug pricing

Furiex second-quarter 2010 revenues increase to $8.1M from $0.2M in second-quarter 2009

Smoking rates continue to fall in Japan

Mental health bill for 2008 was $5.3 billion: Report

HemaQuest commences HQK-1004 global Phase 2 clinical trial in EBV-related malignancies

Event guide: World ADC San Diego eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence